Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4789) 4789
Publication (566) 566
Book Review (68) 68
Book Chapter (27) 27
Magazine Article (12) 12
Dissertation (5) 5
Newspaper Article (5) 5
Conference Proceeding (3) 3
Reference (2) 2
Data Set (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
trastuzumab (4009) 4009
humans (3849) 3849
female (3106) 3106
index medicus (2727) 2727
oncology (2662) 2662
breast neoplasms - drug therapy (2421) 2421
breast cancer (2130) 2130
middle aged (1528) 1528
breast neoplasms - pathology (1465) 1465
antineoplastic combined chemotherapy protocols - therapeutic use (1457) 1457
chemotherapy (1439) 1439
antibodies, monoclonal, humanized (1275) 1275
adult (1259) 1259
cancer (1242) 1242
aged (1207) 1207
receptor, erbb-2 - metabolism (1050) 1050
treatment outcome (927) 927
therapy (893) 893
antibodies, monoclonal - administration & dosage (884) 884
her2 (864) 864
breast neoplasms - metabolism (753) 753
antibodies, monoclonal, humanized - administration & dosage (741) 741
animals (733) 733
antineoplastic agents - therapeutic use (717) 717
care and treatment (661) 661
antineoplastic agents - administration & dosage (660) 660
skin and connective tissue diseases (622) 622
metastasis (603) 603
breast neoplasms - genetics (578) 578
adjuvant chemotherapy (556) 556
research (555) 555
monoclonal-antibody (553) 553
antibodies, monoclonal - therapeutic use (546) 546
trastuzumab - administration & dosage (546) 546
receptor, erbb-2 - genetics (532) 532
cell line, tumor (527) 527
pharmacology & pharmacy (498) 498
disease-free survival (495) 495
survival (489) 489
antineoplastic combined chemotherapy protocols - adverse effects (488) 488
drug therapy (487) 487
mice (480) 480
prognosis (473) 473
cancer therapies (472) 472
paclitaxel - administration & dosage (461) 461
paclitaxel (456) 456
chemotherapy, adjuvant (448) 448
epidermal growth factor (444) 444
taxoids - administration & dosage (431) 431
receptor, erbb-2 - antagonists & inhibitors (426) 426
docetaxel (424) 424
tumors (423) 423
medicine & public health (422) 422
lapatinib (421) 421
breast neoplasms - mortality (415) 415
neoplasm staging (415) 415
neoplasm metastasis (403) 403
antineoplastic agents - adverse effects (399) 399
male (392) 392
breast-cancer (379) 379
neoadjuvant therapy (374) 374
antineoplastic agents (373) 373
aged, 80 and over (367) 367
efficacy (367) 367
trial (358) 358
health aspects (349) 349
receptor, erbb-2 - analysis (349) 349
erbb-2 protein (344) 344
open-label (344) 344
analysis (343) 343
expression (337) 337
antimitotic agents (332) 332
neoplasms (332) 332
metastatic breast-cancer (330) 330
quinazolines - administration & dosage (327) 327
antineoplastic combined chemotherapy protocols - administration & dosage (325) 325
clinical trials (325) 325
safety (319) 319
drug administration schedule (310) 310
antibodies, monoclonal - adverse effects (308) 308
phase-ii (306) 306
hematology, oncology and palliative medicine (301) 301
retrospective studies (297) 297
pertuzumab (294) 294
capecitabine (291) 291
monoclonal antibodies (290) 290
antibodies, monoclonal, humanized - therapeutic use (287) 287
immunohistochemistry (287) 287
patients (285) 285
plus (275) 275
article (272) 272
doxorubicin (271) 271
phase-ii trial (270) 270
antineoplastic agents - pharmacology (266) 266
receptor (265) 265
survival analysis (260) 260
combination (257) 257
deoxycytidine - analogs & derivatives (254) 254
fluorouracil - administration & dosage (253) 253
cardiotoxicity (251) 251
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4514) 4514
Japanese (151) 151
French (60) 60
German (37) 37
Chinese (29) 29
Hungarian (8) 8
Russian (8) 8
Spanish (7) 7
Italian (5) 5
Polish (3) 3
Portuguese (3) 3
Danish (2) 2
Korean (2) 2
Turkish (2) 2
Dutch (1) 1
Hebrew (1) 1
Norwegian (1) 1
Slovak (1) 1
Slovenian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
by Ismael, Gustavo, Dr and Hegg, Roberto, MD and Muehlbauer, Susanne, PhD and Heinzmann, Dominik, PhD and Lum, Bert, PharmD and Kim, Sung-Bae, MD and Pienkowski, Tadeusz, MD and Lichinitser, Mikhail, MD and Semiglazov, Vladimir, MD and Melichar, Bohuslav, MD and Jackisch, Christian, Prof
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 9, pp. 869 - 878
Summary Background A subcutaneous formulation of trastuzumab has been developed, offering potential improvements in patient convenience and resource use... 
Hematology, Oncology and Palliative Medicine | POPULATION | EPIRUBICIN | THERAPY | ONCOLOGY | CHEMOTHERAPY | PACLITAXEL | Cyclophosphamide - administration & dosage | Adenocarcinoma - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Young Adult | Breast Neoplasms - chemistry | Fluorouracil - administration & dosage | Neoplasm Grading | Antibodies, Monoclonal, Humanized - pharmacokinetics | Aged, 80 and over | Adult | Female | Adenocarcinoma - chemistry | Doxorubicin - administration & dosage | Antibodies, Monoclonal, Humanized - therapeutic use | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Infusions, Subcutaneous | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Neoplasm Staging | Trastuzumab | Antimitotic agents | Medical colleges | Oncology, Experimental | Breast cancer | Research | Antineoplastic agents | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline
by Giordano, Sharon H and Temin, Sarah and Kirshner, Jeffrey J and Chandarlapaty, Sarat and Crews, Jennie R and Davidson, Nancy E and Esteva, Francisco J and Gonzalez-Angulo, Ana M and Krop, Ian and Levinson, Jennifer and Lin, Nancy U and Modi, Shanu and Patt, Debra A and Perez, Edith A and Perlmutter, Jane and Ramakrishna, Naren and Winer, Eric P and American Society of Clinical Oncology
Journal of Clinical Oncology, ISSN 0732-183X, 07/2014, Volume 32, Issue 19, pp. 2078 - 2099
Purpose To provide evidence-based recommendations to practicing oncologists and others on systemic therapy for patients with human epidermal growth factor... 
SURVIVAL | WOMEN | TRASTUZUMAB | ONCOLOGY | PROGNOSIS | RECOMMENDATIONS | DISEASE | PHASE-II | LAPATINIB PLUS CAPECITABINE | COMBINATION | PERTUZUMAB | Triazoles - administration & dosage | Health Status Disparities | United States | Humans | Receptors, Estrogen - analysis | Nitriles - administration & dosage | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Societies, Medical | Female | Quinazolines - administration & dosage | Clinical Trials as Topic - standards | Molecular Targeted Therapy - methods | Drug Administration Schedule | Biomarkers, Tumor - analysis | Comorbidity | Maytansine - analogs & derivatives | Antineoplastic Agents, Hormonal - administration & dosage | Treatment Outcome | Evidence-Based Medicine | Breast Neoplasms - drug therapy | Taxoids - administration & dosage | Maytansine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Healthcare Disparities | Breast Neoplasms - mortality | Receptor, ErbB-2 - analysis | Trastuzumab | Index Medicus | ASCO Special
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text U.S. Food and drug administration approval: Neratinib for the extended adjuvant treatment of early-stage HER2-positive breast cancer
by Singh, Harpreet and Walker, Amanda J and Amiri-Kordestani, Laleh and Cheng, Joyce and Tang, Shenghui and Balcazar, Pamela and Barnett-Ringgold, Kimberly and Palmby, Todd R and Cao, Xianhua and Zheng, Nan and Liu, Qi and Yu, Jingyu and Pierce, William F and Daniels, Selena R and Sridhara, Rajeshwari and Ibrahim, Amna and Kluetz, Paul G and Blumenthal, Gideon M and Beaver, Julia A and Pazdur, Richard
Clinical Cancer Research, ISSN 1078-0432, 08/2018, Volume 24, Issue 15, pp. 3486 - 3491
On July 17, 2017, the FDA approved neratinib (NERLYNX; Puma Biotechnology, Inc.) for the extended adjuvant treatment of adult patients with early-stage... 
TRASTUZUMAB | ONCOLOGY | Biotechnology | Regulatory agencies | Toxicity | Medical services | Incidence | Confidence intervals | Randomization | Pain | Vomiting | Appetite | Statistical analysis | Decision making | Invasiveness | Muscles | Diarrhea | Fatigue | Nausea | Breast cancer | FDA approval | Patients | ErbB-2 protein | Spasms | Stomatitis | Breast | Trastuzumab | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study
by Pivot, X and Spano, J.P and Espie, M and Cottu, P and Jouannaud, C and Pottier, V and Moreau, L and Extra, J.M and Lortholary, A and Rivera, P and Spaeth, D and Attar-Rabia, H and Benkanoun, C and Dima-Martinez, L and Esposito, N and Gligorov, J
European Journal of Cancer, ISSN 0959-8049, 09/2017, Volume 82, pp. 230 - 236
HannaH (NCT00950300) and PrefHer (NCT01401166) studies validated the subcutaneous (H-s.c.) formulation of trastuzumab as effective and safe as intravenous... 
Metastatic breast cancer | Subcutaneous | Preference | Trastuzumab | ADJUVANT CHEMOTHERAPY | TRIAL | ONCOLOGY | HANNAH | FOLLOW-UP | OPEN-LABEL | PREFHER | PLUS | Breast Neoplasms - secondary | Humans | Middle Aged | Patient Preference | Trastuzumab - administration & dosage | Antineoplastic Agents - administration & dosage | Breast Neoplasms - drug therapy | Administration, Intravenous | Injections, Subcutaneous | Aged, 80 and over | Quality of Life | Adult | Female | Aged | Oncology, Experimental | Medical care | Breast cancer | Research | Metastasis | Quality management | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
by Robidoux, André, Prof and Tang, Gong, PhD and Rastogi, Priya, MD and Geyer, Charles E, Prof and Azar, Catherine A, MD and Atkins, James N, MD and Fehrenbacher, Louis, MD and Bear, Harry D, MD and Baez-Diaz, Louis, MD and Sarwar, Shakir, MD and Margolese, Richard G, MD and Farrar, William B, Prof and Brufsky, Adam M, Prof and Shibata, Henry R, Prof and Bandos, Hanna, PhD and Paik, Soonmyung, Prof and Costantino, Joseph P, Prof and Swain, Sandra M, Prof and Mamounas, Eleftherios P, Prof and Wolmark, Norman, Prof
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1183 - 1192
Summary Background We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | WOMEN | CELLS | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | ONCOLOGY | GW572016 | CHEMOTHERAPY PLUS TRASTUZUMAB | PERTUZUMAB | INHIBITOR | DOCETAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Puerto Rico | United States | Humans | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Breast Neoplasms - enzymology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Biomarkers, Tumor - metabolism | Mastectomy | Female | Neoadjuvant Therapy | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Odds Ratio | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Drug Administration Schedule | Logistic Models | Treatment Outcome | Chi-Square Distribution | Breast Neoplasms - drug therapy | Canada | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Quinazolines - adverse effects | Trastuzumab | Health maintenance organizations | Neoadjuvant therapy | Medical colleges | Care and treatment | Cyclophosphamide | Anthracyclines | Adjuvant treatment | Breast cancer | Product development | Public health | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
by Baselga, José, Dr and Bradbury, Ian, PhD and Eidtmann, Holger, MD and Di Cosimo, Serena, MD and de Azambuja, Evandro, MD and Aura, Claudia, MD and Gómez, Henry, MD and Dinh, Phuong, MD and Fauria, Karine, PhD and Van Dooren, Veerle, MSc and Aktan, Gursel, MD and Goldhirsch, Aron, MD and Chang, Tsai-Wang, MD and Horváth, Zsolt, MD and Coccia-Portugal, Maria, MD and Domont, Julien, MD and Tseng, Ling-Min, MD and Kunz, Georg, MD and Sohn, Joo Hyuk, MD and Semiglazov, Vladimir, MD and Lerzo, Guillermo, MD and Palacova, Marketa, MD and Probachai, Volodymyr, MD and Pusztai, Lajos, DPhil and Untch, Michael, PhD and Gelber, Richard D, PhD and Piccart-Gebhart, Martine, PhD and NeoALTTO Study Team and Sahlgrenska akademin and Göteborgs universitet and Gothenburg University and Institute of Clinical Sciences, Section for Surgery and Gastrosurgical Research and Education, Department of Surgery and Institutionen för kliniska vetenskaper, sektionen för kirurgi och kirurgisk gastroforskning, Avdelningen för kirurgi and Sahlgrenska Academy
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | APOPTOSIS | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | GW572016 | ERBB2 | INHIBITOR | PLUS | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Medical research | Ligands | Cytotoxicity | Mammography | Kinases | Cancer therapies | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Surgery | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | Diarrhea | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
by Ian E. Krop and Patricia LoRusso and Kathy D. Miller and Shanu Modi and Denise Yardley and Gladys Rodriguez and Ellie Guardino and Michael Lu and Maoxia Zheng and Sandhya Girish and Lukas Amler and Eric P. Winer and Hope S. Rugo
Journal of Clinical Oncology, ISSN 0732-183X, 09/2012, Volume 30, Issue 26, pp. 3234 - 3241
Purpose To determine whether the antibody-drug conjugate trastuzumab emtansine (T-DM1), which combines human epidermal growth factor receptor 2 (HER2)... 
ADJUVANT CHEMOTHERAPY | TRIAL | 1ST-LINE TREATMENT | MAYTANSINE | GENE | ONCOLOGY | RESISTANCE | OVARIAN-CANCER | COMBINATION | PERTUZUMAB | PLUS | Capecitabine | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Male | Antineoplastic Agents - therapeutic use | Breast Neoplasms - metabolism | Neoplasm Metastasis | Anthracyclines - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Adult | Female | Quinazolines - administration & dosage | Molecular Targeted Therapy - methods | Antibodies, Monoclonal, Humanized - therapeutic use | Fluorouracil - analogs & derivatives | Maytansine - analogs & derivatives | Deoxycytidine - administration & dosage | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Immunotoxins - therapeutic use | Breast Neoplasms - pathology | Aged | Bridged-Ring Compounds - administration & dosage | Deoxycytidine - analogs & derivatives | Trastuzumab | Quinazolines - antagonists & inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
by Kazuki N. Sugahara and Tambet Teesalu and Priya Prakash Karmali and Venkata Ramana Kotamraju and Lilach Agemy and Daniel R. Greenwald and Erkki Ruoslahti
Science, ISSN 0036-8075, 5/2010, Volume 328, Issue 5981, pp. 1031 - 1035
Poor penetration of anticancer drugs into tumors can be an important factor limiting their effícacy. We studied mouse tumor models to show that a previously... 
Molecules | Intravenous injections | Medical treatment | REPORTS | Antineoplastics | Antibodies | Liposomes | Dosage | Prostate cancer | Tumors | Cancer | NANOPARTICLES | INTEGRINS | MULTIDISCIPLINARY SCIENCES | MOUSE MODEL | IN-VIVO | DOXORUBICIN | PHAGE DISPLAY | VASCULAR-PERMEABILITY FACTOR | CELL | ENDOTHELIAL GROWTH-FACTOR | DELIVERY | Neoplasms - metabolism | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Neuropilin-1 - metabolism | Albumin-Bound Paclitaxel | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Capillary Permeability - drug effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Albumins - therapeutic use | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - pharmacokinetics | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Oligopeptides - pharmacokinetics | Antibodies, Monoclonal - pharmacokinetics | Albumins - administration & dosage | Neoplasms - blood supply | Oligopeptides - metabolism | Permeability | Paclitaxel - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Albumins - pharmacokinetics | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice | Oligopeptides - administration & dosage | Oligopeptides - pharmacology | Trastuzumab | Antimitotic agents | Peptides | Research | Antineoplastic agents | Drug therapy | Health aspects | Chemotherapy | Drugs | Nanoparticles | Side effects | Doxorubicin | Constraining
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Comparison of subcutaneous and intravenous administration of trastuzumab : A phase i/ib trial in healthy male volunteers and patients with her2-positive breast cancer
by Wynne, Chris and Harvey, Vernon and Schwabe, Christian and Waaka, Devonie and McIntyre, Christine and Bittner, Beate
Journal of Clinical Pharmacology, ISSN 0091-2700, 02/2013, Volume 53, Issue 2, pp. 192 - 201
Trastuzumab is a key component of treatment for human epidermal growth factor receptor 2 (HER2)positive breast cancer in both the early and metastatic... 
Breast cancer | Pharmacokinetics | Subcutaneous | Trastuzumab | HER2-positive | 1ST-LINE TREATMENT | EFFICACY | SAFETY | breast cancer | RECEPTOR | CHEMOTHERAPY | trastuzumab | subcutaneous | THERAPY | pharmacokinetics | PHARMACOLOGY & PHARMACY | PLUS | Antibodies, Monoclonal, Humanized - adverse effects | Area Under Curve | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Breast Neoplasms - drug therapy | Young Adult | Administration, Intravenous | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Antineoplastic Agents - adverse effects | Injections, Subcutaneous | Adolescent | Breast Neoplasms - blood | Adult | Female | Aged | Antineoplastic Agents - pharmacokinetics | Receptor, ErbB-2 | Drug therapy | Research | Ovarian cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands
by Franken, Margreet G and Kanters, Tim A and Coenen, Jules L and de Jong, Paul and Koene, Harry R and Lugtenburg, Pieternella J and Jager, Agnes and Uyl-de Groot, Carin A
Anti-Cancer Drugs, ISSN 0959-4973, 09/2018, Volume 29, Issue 8, pp. 791 - 801
There is little evidence on the costs associated with the route of administration of oncology drugs. We investigated time and resource use for hospitals and... 
Non-Hodgkin lymphoma | Healthcare costs | Intravenous | Subcutaneous | Rituximab | Human epidermal growth factor receptor-2 positive breast cancer | Societal costs | Administration costs | Microcosting | Trastuzumab | administration costs | microcosting | societal costs | EFFICACY | SAFETY | non-Hodgkin lymphoma | OPEN-LABEL | TIME | healthcare costs | RESOURCE UTILIZATION | subcutaneous | trastuzumab | BREAST-CANCER | intravenous | MOTION | ONCOLOGY | human epidermal growth factor receptor-2 positive breast cancer | LYMPHOMA | PHARMACOLOGY & PHARMACY | rituximab | Drugs | Medical research | Drug delivery systems | Care and treatment | Economic aspects | Medicine, Experimental | Research | Comparative analysis | Medical economics | Cancer | Vehicles
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Trastuzumab administration during pregnancy: a systematic review and meta-analysis
by Zagouri, Flora and Sergentanis, Theodoros N and Chrysikos, Dimosthenis and Papadimitriou, Christos A and Dimopoulos, Meletios-Athanassios and Bartsch, Rupert
Breast Cancer Research and Treatment, ISSN 0167-6806, 1/2013, Volume 137, Issue 2, pp. 349 - 357
Landmark studies have established trastuzumab in the treatment of HER2-positive breast cancer. The present systematic review and meta-analysis aims to... 
Pregnancy | Oncology | Breast cancer | Medicine & Public Health | Oligohydramnios | Trastuzumab | DIAGNOSIS | CHEMOTHERAPY | ADJUVANT TRASTUZUMAB | PACLITAXEL | TRIAL | GROWTH-FACTOR RECEPTOR | THERAPY | ONCOLOGY | METASTATIC BREAST-CANCER | EXPRESSION | Antibodies, Monoclonal, Humanized - adverse effects | Prenatal Exposure Delayed Effects | Antibodies, Monoclonal, Humanized - therapeutic use | Follow-Up Studies | Infant Mortality | Humans | Antineoplastic Agents - therapeutic use | Maternal Exposure | Pregnancy Trimester, First | Birth Weight | Antineoplastic Agents - adverse effects | Pregnancy Complications, Neoplastic - drug therapy | Female | Infant, Newborn | Care and treatment | Pregnant women | Analysis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
by Bella Kaufman and John R. Mackey and Michael R. Clemens and Poonamalle P. Bapsy and Ashok Vaid and Andrew Wardley and Sergei Tjulandin and Michaela Jahn and Michaela Lehle and Andrea Feyereislova and Cédric Révil and Alison Jones
Journal of Clinical Oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 33, pp. 5529 - 5537
Purpose TAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth... 
TRIAL | AROMATASE INHIBITOR | THERAPY | ONCOLOGY | SERUM HER-2/NEU | TAMOXIFEN | RESISTANCE | HER2 | COMBINATION | ESTROGEN-RECEPTOR | ENDOCRINE TREATMENT | Receptors, Estrogen - blood | Triazoles - administration & dosage | Triazoles - adverse effects | Confidence Intervals | Postmenopause - drug effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antibodies, Monoclonal, Humanized | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Adenocarcinoma - metabolism | Statistics, Nonparametric | Aged, 80 and over | Female | Drug Administration Schedule | Administration, Oral | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Adenocarcinoma - secondary | Biomarkers, Tumor - blood | Disease-Free Survival | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Breast Neoplasms - pathology | Survival Analysis | Breast Neoplasms - mortality | Aged | Infusions, Intravenous | Nitriles - adverse effects | Receptors, Progesterone - blood | Receptor, ErbB-2 - blood | Trastuzumab | Adenocarcinoma - mortality | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial
by Loibl, Sibylle and Jackisch, C and Schneeweiss, A and Schmatloch, S and Aktas, B and Denkert, C and Wiebringhaus, H and Kümmel, S and Warm, M and Paepke, S and Just, M and Hanusch, C and Hackmann, J and Blohmer, J.-U and Clemens, M and Dan Costa, S and Gerber, B and Engels, K and Nekljudova, V and von Minckwitz, G and Untch, M and Investigators German Breast Grp GB and AGO B Study Groups and investigators of the German Breast Group (GBG) and the Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) study groups and on behalf of the investigators of the German Breast Group (GBG) and the Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) study groups
Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 3, pp. 497 - 504
Background: The neoadjuvant phase III GeparSepto study showed that substituting nab-paclitaxel for standard solvent-based paclitaxel significantly improved the... 
Neoadjuvant chemotherapy | Pertuzumab | Early breast cancer | Trastuzumab | early breast cancer | MULTICENTER | CARBOPLATIN | OPEN-LABEL | DOCETAXEL | PLUS TRASTUZUMAB | PATHOLOGICAL COMPLETE RESPONSE | trastuzumab | LAPATINIB | neoadjuvant chemotherapy | ONCOLOGY | pertuzumab | HER2 | CARCINOMA | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Albumins - administration & dosage | Trastuzumab - administration & dosage | Epirubicin - administration & dosage | Breast Neoplasms - drug therapy | Anthracyclines - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Breast Neoplasms - genetics | Fluorouracil - administration & dosage | Breast Neoplasms - pathology | Female | Neoadjuvant Therapy | Aged | Receptor, ErbB-2 - antagonists & inhibitors | Neoplasm Staging | Paclitaxel - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights